Study of Roxadustat in the Treatment of Acute Myocardial Infarction

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Roxadustat in Patients With Acute ST Elevation Myocardial Infarction

Depite successful primary percutaneous coronary intervention (PCI) and standardized medical treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor, with high morality and various complications such as heart failure. Roxadustat is a new drug targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition and has shown promising effect in reducing infarct size in pre-clinical studies.

This study aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

This study is an open-label, paralleled, randomized controlled trial. It aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

Inclusion Criteria:

• Acute STEMI (ST segment elevation myocardial infarction) diagnosed by ST elevation
• Coronary angiography within 12 hours of symptom onset, with TIMI flow grade 0 - 1 of culprit vessel
• Primary PCI with TIMI flow grade 2 - 3 after successful intervention
• Capable and willing to provide informed consent and capable of completing study visits

Exclusion Criteria:

• Previous acute myocardial infarction history
• Cardiogenic Shock at admission
• Previously treated by roxadustat
• Contraindications of roxadustat treatment
• Contraindication of Cardiac MRI (e.g. eGFR < 30 ml/min, pacemaker, metal prosthesis, etc.)